Open-Angle Glaucoma (OAG) Market Report 2026

The open-angle glaucoma (oag) market size has grown strongly in recent years. It will grow from $6.53 billion in 2025 to $6.96 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to limited access to in-person mental health services, rising prevalence of anxiety and depression, increasing awareness of mental health importance, growing use of early telemedicine platforms, early adoption of online counseling programs.

The open-angle glaucoma (oag) market size is expected to see strong growth in the next few years. It will grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising demand for accessible online therapy, increasing adoption of mobile and web-based counseling tools, growing integration of ai-powered mental wellness solutions, rising use of hybrid therapy models combining individual and group sessions, expansion of online therapy offerings in commercial and residential segments. Major trends in the forecast period include rising adoption of prostaglandin analog drugs, increasing use of minimally invasive glaucoma surgeries, growing awareness about early diagnosis and screening, rising teleophthalmology consultations for oag management, increasing development of combination drug therapies.

The increasing awareness of eye diseases is expected to drive growth in the open-angle glaucoma (OAG) market in the coming years. Eye diseases include conditions affecting the structure, function, or vision of the eyes, ranging from mild issues such as dry eye to severe disorders like glaucoma and macular degeneration. Their prevalence is rising due to aging populations, prolonged screen time, increasing diabetes cases, environmental pollution, and lifestyle factors that strain eye health. Open-angle glaucoma, a leading cause of blindness - particularly among older adults - highlights the importance of routine eye exams, early diagnosis, and proactive treatment to prevent irreversible vision loss. For example, in October 2023, the Royal National Institute of Blind People (RNIB), a UK-based sight loss charity, reported that eye care outpatient appointments in the UK exceeded eight million in 2021/22, making it the most in-demand specialty. Additionally, the number of individuals with sight loss, currently over two million, is projected to exceed four million by 2050. Therefore, growing awareness of eye diseases is propelling growth in the OAG market.

Key companies in the OAG market are focusing on innovative devices, such as minimally invasive glaucoma devices (MIGDs), to offer advanced, less invasive treatment alternatives for managing primary open-angle glaucoma while reducing reliance on conventional therapies. MIGDs are surgical implants and techniques designed to lower intraocular pressure through small incisions with minimal tissue disruption. For instance, in December 2023, iSTAR Medical, a Belgium-based medtech company, launched MINIject in the Netherlands. This bio-integrating device uses a unique porous STAR material to improve fluid outflow and reduce intraocular pressure, representing a safer, more effective approach to glaucoma management.

In July 2024, Alcon Inc., a Switzerland-based ophthalmology company, acquired BELKIN Vision Ltd. for $81 million. This acquisition strengthens Alcon's glaucoma treatment portfolio by adding the direct selective laser trabeculoplasty (DSLT) device, a first-line laser therapy for managing open-angle glaucoma. The acquisition supports Alcon’s strategy to expand global access to innovative and minimally invasive glaucoma treatments. BELKIN Vision Ltd., based in Israel, specializes in devices for open-angle glaucoma management.

Major companies operating in the open-angle glaucoma (oag) market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Alcon Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Santen Pharmaceuticals, Théa Pharma, Glaukos Corporation, Quantel Medical, EyePoint Pharmaceuticals Inc., iSTAR Medical, Nicox Ophthalmics, Visus Therapeutics, Inotek Pharmaceuticals, Hoya Corporation, Boston Scientific, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, Topcon Corporation, Nidek Co. Ltd., Heidelberg Engineering GmbH, New World Medical Inc.

North America was the largest region in the open-angle glaucoma (OAG) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the open-angle glaucoma (oag) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the open-angle glaucoma (oag) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the online therapy services market by impacting the cost of telecommunication tools, software platforms, and digital infrastructure used by providers, particularly affecting north america, europe, and asia-pacific regions. While tariffs can raise operational costs, they also promote the development of domestic digital therapy platforms, drive innovation in cost-efficient solutions, and expand the availability of localized online mental health services.

The open-angle glaucoma (oag) market research report is one of a series of new reports that provides open-angle glaucoma (oag) market statistics, including open-angle glaucoma (oag) industry global market size, regional shares, competitors with a open-angle glaucoma (oag) market share, detailed open-angle glaucoma (oag) market segments, market trends and opportunities, and any further data you may need to thrive in the open-angle glaucoma (oag) industry. This open-angle glaucoma (oag) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Open-angle glaucoma (OAG) is a chronic, progressive eye disease marked by gradual blockage of the eye’s drainage canals, causing increased intraocular pressure that damages the optic nerve. Often, symptoms are not noticeable until significant vision loss occurs. Treatment focuses on lowering intraocular pressure to prevent optic nerve damage and preserve vision, using medications, laser procedures, or surgical interventions.

The main disease types in open-angle glaucoma include open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma is characterized by elevated intraocular pressure that gradually harms the optic nerve, potentially leading to vision loss, often without early warning signs. Drug classes used for treatment include prostaglandin analogs, beta blockers, adrenergic agonists, carbonic anhydrase inhibitors, and others. End users include hospitals, homecare services, specialty clinics, and others, with distribution through hospital pharmacies, online pharmacies, and retail pharmacies.

The open-angle glaucoma (OAG) market consists of revenues earned by entities by providing services such as optometric services, surgical interventions, medication management, and patient education and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The open-angle glaucoma (OAG) market also includes sales of tonometers, visual field analyzers, and lubricating eye drops. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.